Search
Astemizole
go.drugbank.com/drugs/DB00637ApprovedWithdrawnIt was withdrawn from market by the manufacturer in 1999 due to the potential to cause arrhythmias at high doses, especially when when taken with CYP inhibitors or grapefruit juice. … Astemizole is a long-acting, non-sedating second generation antihistamine used in the treatment of allergy symptoms.
Doxorubicin
go.drugbank.com/drugs/DB00997ApprovedInvestigational[A257614] Thanks to its efficacy and broad effect, doxorubicin was approved by the FDA in 1974 to treat a variety of cancer, including but not limited to breast, lung, gastric, ovarian, thyroid, non-Hodgkin … [A257709] Although its detailed molecular mechanisms have yet to be understood, doxorubicin is generally thought to exert its effect through DNA intercalation, which eventually leads to DNA damage and
Dofetilide
go.drugbank.com/drugs/DB00204ApprovedInvestigationalDofetilide is a class III antiarrhythmic agent that is approved by the Food and Drug Administration (FDA) for the maintenance of sinus rhythm in individuals prone to the formation of atrial fibrillation … and flutter, and for the chemical cardioversion to sinus rhythm from atrial fibrillation and flutter.
Triamterene
go.drugbank.com/drugs/DB00384ApprovedIt works by promoting the excretion of sodium ions and water while decreasing the potassium excretion in the distal part of the nephron in the kidneys by working on the lumenal side. … [L6163] Triamterene was approved by the Food and Drug Administration in the U.S. in 1964.
Mixtures: TRIAMETERENO E HIDROCLOROTIAZIDA CAPSULASLactulose
go.drugbank.com/drugs/DB00581ApprovedInvestigational[L6202] Especially considering the use of lactulose as a laxative is typically only considered after lifestyle and dietary modifications fail and the fact that lactulose therapy cannot be ethically … withheld from patients diagnosed with PSE in a placebo study, the substance may just be one of many options available for treating constipation and its efficacy in managing PSE may never be formally confirmed
Products: FLOROLAC 670MG/ML LOES Z EModified vaccinia ankara
go.drugbank.com/drugs/DB15483ApprovedInvestigationalModified Vaccinia Ankara (MVA) refers to an attenuated strain of the Vaccinia virus.
Chlorthalidone
go.drugbank.com/drugs/DB00310ApprovedInvestigationalChlorthalidone improves blood pressure and swelling by preventing water absorption from the kidneys through inhibition of the Na+/Cl− symporter in the distal convoluted tubule cells in the kidney. … be partly the result of reductions in carbonic anhydrase–dependent pathways.
Mixtures: ATENOLOLO E CLORTALIDONE MYLAN GENERICS, ATENOLOLO E CLORTALIDONE MYLAN GENERICSButenafine
go.drugbank.com/drugs/DB01091ApprovedIn particular, butenafine acts to inhibit the activity of the squalene epoxidase enzyme that is essential in the formation of sterols necessary for fungal cell membranes. … Butenafine's mechanism of action is believed to involve the synthesis inhibition of sterols.
Cefepime
go.drugbank.com/drugs/DB01413ApprovedInvestigational[A249050] The popularity of its third-generation predecessors, its clinical efficacy, and the high prevalence of multidrug-resistant bacteria might be some of the factors leading to an increase in the … The activity of cefepime against Enterobacteriaceae, _Pseudomonas aeruginosa_, and _Staphylococcus aureus_ is due to its high stability toward beta-lactamases.
Products: ROXIPIME 2 G IV ENJEKSIYON VE INFÜZYON IÇIN TOZ IÇEREN FLAKON ,1 ADET, ROXIPIME 2 G IV ENJEKSIYON VE INFÜZYON IÇIN TOZ IÇEREN FLAKON ,10 ADETAlpelisib
go.drugbank.com/drugs/DB12015ApprovedInvestigationalAlpelisib was designed to target this enzyme that appears to be mutated at a rate of nearly 30% in human cancers, leading to hyperactivation. … To initiate alpelisib therapy, it is required that the presence of a PIK3CA mutation in the tissue and/or liquid biopsy sample collection should be confirmed via FDA-approved diagnostic tests.